跳至主要内容
临床试验/NCT01032486
NCT01032486已完成不适用

An Open-Label, Multi-Center, Single Arm Study to Evaluate the Effects of Azilect® on Sleep Disturbances in Parkinson's Disease Subjects

Teva Branded Pharmaceutical Products R&D, Inc.0 个研究点目标入组 120 人开始时间: 2009年12月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
120
主要终点
Change from baseline to end of the study in sleep disturbances as measured with the Parkinson's Disease Sleep Scale (PDSS).

研究概览

简要总结

The main objective of this study is to evaluate the effect of Azilect® on sleep disturbances in Parkinson's Disease patients, after 2 months of treatment.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

性别
All
接受健康志愿者

入选标准

  • idiopathic Parkinson's disease.
  • eligible to Azilect® treatment as per Canadian product monograph

排除标准

  • exclusion (e.g. drug-drug interactions, contraindications, warnings and precautions) based on the Canadian product monograph.
  • investigational drug within 30 days prior to study
  • use of Azilect® or selegiline within 60 days prior to study
  • significant medical condition

研究组 & 干预措施

Azilect

Subjects with a diagnosis of idiopathic Parkinson's disease eligible to Azilect® treatment based on the investigator's clinical assessment and according to the Canadian product monograph.

干预措施: Rasagiline mesylate (Drug)

结局指标

主要结局

Change from baseline to end of the study in sleep disturbances as measured with the Parkinson's Disease Sleep Scale (PDSS).

时间窗: 2 months

次要结局

  • Change from baseline to end of the study in daytime sleepiness as measured with the Epworth Sleepiness Scale (ESS).(2 months)

研究者

申办方类型
Industry
责任方
Sponsor

相似试验